Nektar Therapeutics (NKTR) Stock Forecast & Price Target

Compare

1,285 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NKTR Analyst Ratings

Strong Buy

5 Buy

1 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Nektar

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NKTR Stock 12 Month Forecast

Average Price Target

$5.10

▲(661.19%Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is $5.10 with a high forecast of $7.00 and a low forecast of $2.00. The average price target represents a 661.19% change from the last price of $0.67.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.78,1.2584615384615385,1.7369230769230768,2.2153846153846155,2.693846153846154,3.172307692307692,3.6507692307692308,4.1292307692307695,4.607692307692307,5.086153846153846,5.564615384615385,6.0430769230769235,6.521538461538461,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.78,1.1123076923076922,1.4446153846153846,1.7769230769230768,2.109230769230769,2.441538461538461,2.7738461538461534,3.1061538461538456,3.438461538461538,3.77076923076923,4.103076923076922,4.435384615384614,4.7676923076923075,{"y":5.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.78,0.8738461538461538,0.9676923076923077,1.0615384615384615,1.1553846153846155,1.2492307692307691,1.343076923076923,1.436923076923077,1.5307692307692307,1.6246153846153846,1.7184615384615385,1.8123076923076924,1.906153846153846,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.47,"date":1698796800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.47,"date":1701388800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.78,"date":1709251200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1717200000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.83,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.84,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.64,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.78,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$7.00

Average Price Target$5.10

Lowest Price Target$2.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$0.5

Hold

-25.37%

Downside

Reiterated

05/29/25

Nektar Therapeutics' overall stock score reflects the company's substantial financial challenges, including declining revenues and high leverage. Technical analysis indicates potential resistance, while valuation metrics are unattractive due to a negative P/E ratio. Despite some positive developments in their pipeline and a strong cash position, significant risks remain, including litigation and non-cash losses.

Yasmeen RahimiPiper Sandler

Piper Sandler

Buy

944.78%

Upside

Reiterated

05/19/25

Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)

Arthur He CFAH.C. Wainwright

H.C. Wainwright

$6.5

Buy

870.15%

Upside

Reiterated

05/12/25

Anticipated Clinical Trial Results and Financial Stability Justify Buy Rating for Nektar Therapeutics

Andy HsiehWilliam Blair

William Blair

―

Hold

―

Reiterated

05/12/25

William Blair Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)

Julian HarrisonBTIG

BTIG

Buy

497.01%

Upside

Reiterated

05/09/25

BTIG reiterates Buy Rating on Nektar Therapeutics (NKTR)BTIG analyst Julian Harrison reiterated a Buy rating and $4.00 price target on Nektar Therapeutics (NASDAQ: NKTR).

Roger SongJefferies

Jefferies

$1→$2

Buy

198.51%

Upside

Upgraded

04/11/25

Nektar upgraded to Buy from Hold at JefferiesNektar upgraded to Buy from Hold at Jefferies

Jay OlsonOppenheimer

Oppenheimer

Buy

795.52%

Upside

Upgraded

03/14/25

Nektar upgraded at Oppenheimer on upcoming mid-stage trial readoutOppenheimer upgraded the biopharma to Outperform from Perform, citing a favorable valuation setup ahead of a mid-stage trial readout for its eczema therapy rezpegaldesleukin.

Mayank MamtaniB.Riley Financial

B.Riley Financial

Buy

497.01%

Upside

Reiterated

02/28/25

Analysts Conflicted on These Healthcare Names: Lemaitre Vascular (NASDAQ: LMAT), Catalyst Pharma (NASDAQ: CPRX) and Nektar Therapeutics (NASDAQ: NKTR)

Jessica FyeJ.P. Morgan

J.P. Morgan

―

Sell

―

Reiterated

02/24/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fresenius Medical Care (NYSE: FMS), Herbalife (NYSE: HLF) and Nektar Therapeutics (NASDAQ: NKTR)

Anthony ButlerRodman & Renshaw

Rodman & Renshaw

Buy

198.51%

Upside

Initiated

06/28/24

Nektar initiated with a Buy at Rodman & RenshawNektar initiated with a Buy at Rodman & Renshaw

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$0.5

Hold

-25.37%

Downside

Reiterated

05/29/25

Yasmeen RahimiPiper Sandler

Piper Sandler

Buy

944.78%

Upside

Reiterated

05/19/25

Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)

Arthur He CFAH.C. Wainwright

H.C. Wainwright

$6.5

Buy

870.15%

Upside

Reiterated

05/12/25

Anticipated Clinical Trial Results and Financial Stability Justify Buy Rating for Nektar Therapeutics

Andy HsiehWilliam Blair

William Blair

―

Hold

―

Reiterated

05/12/25

William Blair Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)

Julian HarrisonBTIG

BTIG

Buy

497.01%

Upside

Reiterated

05/09/25

BTIG reiterates Buy Rating on Nektar Therapeutics (NKTR)BTIG analyst Julian Harrison reiterated a Buy rating and $4.00 price target on Nektar Therapeutics (NASDAQ: NKTR).

Roger SongJefferies

Jefferies

$1→$2

Buy

198.51%

Upside

Upgraded

04/11/25

Nektar upgraded to Buy from Hold at JefferiesNektar upgraded to Buy from Hold at Jefferies

Jay OlsonOppenheimer

Oppenheimer

Buy

795.52%

Upside

Upgraded

03/14/25

Mayank MamtaniB.Riley Financial

B.Riley Financial

Buy

497.01%

Upside

Reiterated

02/28/25

Analysts Conflicted on These Healthcare Names: Lemaitre Vascular (NASDAQ: LMAT), Catalyst Pharma (NASDAQ: CPRX) and Nektar Therapeutics (NASDAQ: NKTR)

Jessica FyeJ.P. Morgan

J.P. Morgan

―

Sell

―

Reiterated

02/24/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fresenius Medical Care (NYSE: FMS), Herbalife (NYSE: HLF) and Nektar Therapeutics (NASDAQ: NKTR)

Anthony ButlerRodman & Renshaw

Rodman & Renshaw

Buy

198.51%

Upside

Initiated

06/28/24

Nektar initiated with a Buy at Rodman & RenshawNektar initiated with a Buy at Rodman & Renshaw

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nektar Therapeutics

1 Month

xxx

Success Rate

9/17 ratings generated profit

Average Return

+1.59%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 52.94% of your transactions generating a profit, with an average return of +1.59% per trade.

3 Months

xxx

Success Rate

9/17 ratings generated profit

Average Return

+6.82%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +6.82% per trade.

1 Year

Jessica FyeJ.P. Morgan

Success Rate

12/17 ratings generated profit

Average Return

+52.94%

reiterated a sell rating 3 months ago

Copying Jessica Fye's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +52.94% per trade.

2 Years

xxx

Success Rate

12/17 ratings generated profit

Average Return

+57.66%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 70.59% of your transactions generating a profit, with an average return of +57.66% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NKTR Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NKTR has received 10 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. NKTR average Analyst price target in the past 3 months is 5.10.

Each month's total comprises the sum of three months' worth of ratings.

NKTR Financial Forecast

NKTR Earnings Forecast

Next quarter’s earnings estimate for NKTR is -$0.20 with a range of -$0.25 to -$0.17. The previous quarter’s EPS was -$0.24. NKTR beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.71% of the time in the same period. In the last calendar year NKTR has Outperformed its overall industry.

NKTR Sales Forecast

Next quarter’s sales forecast for NKTR is $9.74M with a range of $0.00 to $12.09M. The previous quarter’s sales results were $10.46M. NKTR beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.90% of the time in the same period. In the last calendar year NKTR has Outperformed its overall industry.

NKTR Stock Forecast FAQ

What is NKTR’s average 12-month price target, according to analysts?

Based on analyst ratings, Nektar Therapeutics’s 12-month average price target is 5.10.

What is NKTR’s upside potential, based on the analysts’ average price target?

Nektar Therapeutics has 661.19% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NKTR a Buy, Sell or Hold?

Nektar Therapeutics has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.

What is Nektar Therapeutics’s price target?

The average price target for Nektar Therapeutics is 5.10. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $7.00 ,the lowest forecast is $2.00. The average price target represents 661.19% Increase from the current price of $0.67.

What do analysts say about Nektar Therapeutics?

Nektar Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of NKTR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Nektar Therapeutics (NKTR) Stock Forecast & Price Target

NKTR Analyst Ratings

NKTR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Nektar Therapeutics

NKTR Analyst Recommendation Trends

NKTR Financial Forecast

NKTR Earnings Forecast

NKTR Sales Forecast

NKTR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts